Please login first
Heather Elliott   Dr.  Graduate Student or Post Graduate 
Timeline See timeline
Heather Elliott published an article in September 2018.
Top co-authors
Tarah Wright

34 shared publications

Department of Environmental Science, Dalhousie University, Halifax, Canada)

Alasdair P. MacGowan

14 shared publications

North Bristol NHS Trust, Brunel Building, Southmead Hospital, Westbury-on-Trym, Bristol, BS10 5NB, ᅟ.

Jennifer Bernstein

8 shared publications

Spatial Sciences Institute, University of Southern California, Los Angeles, USA

Publication Record
Distribution of Articles published per year 
(2011 - 2018)
Total number of journals
published in
Article 0 Reads 0 Citations Canadian Student Leaders’ Conceptualizations of Sustainability and Sustainable Universities Heather Elliott, Tarah Wright Published: 01 September 2018
Journal of Education for Sustainable Development, doi: 10.1177/0973408218792125
DOI See at publisher website
Article 0 Reads 1 Citation Wellness as a Worldwide Phenomenon? Heather Elliott, Jennifer Bernstein, Diana M. Bowman Published: 01 January 2014
Journal of Health Politics, Policy and Law, doi: 10.1215/03616878-2813732
DOI See at publisher website PubMed View at PubMed
CONFERENCE-ARTICLE 8 Reads 1 Citation Barriers to Sustainable Universities and Ways Forward: A Canadian students’ Perspective Heather Elliott, Tarah Wright Published: 06 November 2013
The 3rd World Sustainability Forum, doi: 10.3390/wsf3-f006
DOI See at publisher website ABS Show/hide abstract
While efforts to integrate Education for Sustainable Development (ESD) at universities have been increasing, said integration has not been occurring fast enough to counteract the unbalanced nature of humanity’s interactions with the planet. A number of studies have delved into the possible barriers slowing this progress and incentives to increasing sustainability initiatives on campus, but rarely have they included the student perspective. This knowledge gap was addressed as part of a study that utilized semi-structured interviews and concept checklists with 27 Canadian university students’ unions’ presidents to investigate their conceptualizations of sustainable development and sustainable universities. Thematic analysis utilizing an inductive approach was employed to discover key themes. While a number of themes emerged, one that was overarching as a general concern and both a barrier and incentive to a more sustainable university was university finances. This in turn is connected to students through enrolment and recruitment efforts as tuition represents a large proportion of university budgets. Participants believed students hold the greatest ability of all university stakeholders to promote sustainability on their campuses and when combined with their ability to impact university finances, the possible impact of empowered students to initiate change for more sustainable campuses is great. In order to harness this energy, this study makes recommendations to further enable students to engage with and mobilize their university campuses and stakeholders. Even potential students could influence universities by demanding deeper commitments to sustainability. This research contributes to scholarly research by presenting the perspectives of an understudied, yet important, university stakeholder group regarding factors influencing campus sustainability and recommendations for student empowerment. This research was part of a larger SSHRC-funded study investigating university stakeholders’ conceptualizations of sustainable development, sustainable universities and the role of universities in the journey towards a more sustainable future.
Article 0 Reads 4 Citations Pharmacodynamics of the Antibacterial Effect of and Emergence of Resistance to Doripenem in Pseudomonas aeruginosa and A... Karen E. Bowker, Alan R. Noel, Sharon G. Tomaselli, Heather ... Published: 19 June 2012
Antimicrobial Agents and Chemotherapy, doi: 10.1128/aac.06111-11
DOI See at publisher website PubMed View at PubMed ABS Show/hide abstract
Anin vitrodilutional pharmacokinetic model of infection was used to study the pharmacodynamics of doripenem in terms of the ability to killPseudomonas aeruginosaorAcinetobacter baumanniiand also changes in their population profiles. In dose-ranging studies, the cumulative percentages of a 24-h period that the drug concentration exceeds the MIC under steady-state pharmacokinetic conditions (TMICs) required for doripenem to produce a 24-h bacteriostatic effect and a −2-log-unit reduction in viable count were 25% ± 11% and 35% ± 13%, respectively, forP. aeruginosa(MIC range, 0.24 to 3 mg/liter) and 20% ± 11% and 33% ± 12%, respectively, forAcinetobacterspp. (MIC range, 0.45 to 3.0 mg/liter). ATMICof >40 to 50% produced a maximum response with both species at 24 h or 48 h of exposure. After 24 h of exposure to doripenem at aTMICin the range of 12.5 to 37.5%,P. aeruginosaandA. baumanniipopulation profiles revealed mutants able to grow on 4× MIC-containing medium; such changes were further amplified by 48 h of exposure. Dose-fractionation experiments targetingTMICs of 12.5%, 25%, or 37.5% as six exposures, two exposures, or a single exposure over 48 h with a single strain ofP. aeruginosaindicated that changes in population profiles were greatest with multiple exposures atTMICtargets of 12.5 or 25%. In contrast, multiple exposures at 37.5%TMICmost effectively suppressed total bacterial counts and changes in population profiles. Simulations of human doses of doripenem of 500 mg, 1,000 mg, 2,000 mg, and 3,000 mg every 8 h over 96 h showed marked initial killing up to 6 h but growback thereafter. Changes in population profiles occurred only in the regimen of 500 mg every 8 h againstP. aeruginosabut occurred with all dose regimens forA. baumanniistrains. A doripenemTMICof ≥40 to 50% is maximally effective in killingP. aeruginosaorA. baumanniiand suppressing changes in population profiles in short-term experiments for up to 48 h; however, aTMICof 12.5 to 25% amplifies population changes, especially with exposures every 8 h. In longer-term experiments, up to 96 h, even doripenem doses of 4 to 6 times those used in human studies proved incapable of pathogen eradication and prevention of changes in population profiles. The association of aTMICof 25 to 37.5% with changes in population profiles has implications in terms of future clinical breakpoint setting.
Article 2 Reads 7 Citations Pharmacodynamics of Razupenem (PZ601) Studied in anIn VitroPharmacokinetic Model of Infection Alasdair P. MacGowan, Alan Noel, Sharon Tomaselli, Heather E... Published: 24 January 2011
Antimicrobial Agents and Chemotherapy, doi: 10.1128/aac.00936-10
DOI See at publisher website PubMed View at PubMed ABS Show/hide abstract
Simulations of administration of razupenem at 1 g every 12 h by 1-h intravenous (i.v.) infusion were performed in anin vitropharmacokinetic model of infection. The antibacterial effect of this razupenem dosing regimen against six strains ofStaphylococcus aureus(one methicillin-sensitiveS. aureus[MSSA] strain [MIC, 0.015 μg/ml] and five methicillin-resistantS. aureus[MRSA] strains [MIC range, 0.09 to 3 μg/ml]) and five strains ofEnterobacteriaceae(threeEscherichia colistrains [two containing extended-spectrum β-lactamases {ESBLs}] and twoEnterobactersp. strains [one with an AmpC enzyme and the other with a raised razupenem MIC; MIC range, 0.09 to 6 μg/ml]) was assessed. Against the MSSA and MRSA strains, razupenem produced a >3.5-log-unit reduction in viable count after 24 h. There were no changes in population profiles. In a second series of experiments, over 5 days there was rapid initial clearance of MRSA from the model followed by regrowth after 48 h. MRSA colonies appeared on 2× MIC recovery medium after 72 h with strain 33820 (MIC, 3.0 μg/ml) and at 120 h with strain 27706 (MIC, 1.5 μg/ml). AgainstE. coliandEnterobacterspp., razupenem produced a >3.5-log-unit reduction in bacterial counts for all strains except that with an MIC of 6 μg/ml, where razupenem had a notably poorer antibacterial effect. Population profiles were unchanged after 48 h of exposure to razupenem except forEnterobacterstrain 34425 (MIC, 6.0 μg/ml), where colonies were recovered from media containing 2×, 4×, and 8× MIC. In dose-ranging studies with MRSA strains, the percentage of the dosing interval that the free drug concentration remained higher than the pathogen MIC (fT>MIC) for a 24-h bacteriostatic effect was 5.0% ± 1.4%, and that for a 1-log-unit reduction in count was 12.5% ± 5.8%. Population profiles indicated growth on 2× MIC recovery medium atfT>MIC values of 1 to 35% but not at a value of >35%. In a similar set of experiments withEnterobacteriaceae, thefT>MIC for a 24-h bacteriostatic effect was 34.2% ± 7.6% and that for a 1-log-unit reduction in count was 42.5% ± 7.8%. Population analysis profiles indicated growth on recovery media with 2×, 4×, and 8× MIC atfT>MICs in the range of 1 to 69% but rarely at values of ≥70%. In conclusion, razupenem at simulated human doses of 1 g i.v. every 12 h has a marked antibacterial effect on MSSA and MRSA strains with MICs of ≤3.0 μg/ml andEnterobacteriaceaewith MICs of ≤0.4 μg/ml.fT>MIC targets of ≥35% for MRSA and ≥70% forEnterobacteriaceaeshould provide significant antibacterial effects combined with low risks of changing pathogen antibiotic population profiles.